arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Sonoma Pharmaceuticals, Inc.

SNOA
$1.42 ▲ +0.19 (+15.45%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
63 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sonoma Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 48.1%
Op. Margin -6.3%
ROIC -13.3%
FCF / Share None
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity 0.07
info Valuation on last close. End-of-day price, Aug 7, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.56M
↑ +48.1%
Net Income Profit after all expenses
$-581.00K
↑ +25.1%
Operating Margin Operating profit as % of sales
-6.3%
↑ +59.5% 11th
FCF / Share Free cash flow per share
$-0.47
↓ -20.8%
Long-Term Debt Long-term obligations
$15.00K
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
6
Financial Health
44
Cash Quality
72

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 63 quarters